Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study
Authors:
- Marco GalluzzoMarco Galluzzo
- Emanuele TrovatoETEmanuele Trovato
- Marina TalamontiMTMarina Talamonti
- Giacomo CaldarolaGCGiacomo Caldarola
- Lucia Di NardoLNLucia Di Nardo
- Laura LazzeriLLLaura Lazzeri
- Cristina MughedduCMCristina Mugheddu
- Martina BurlandoMBMartina Burlando
- Riccardo BalestriRBRiccardo Balestri
- Nicoletta BernardiniNBNicoletta Bernardini
- Gabriele BiondiGBGabriele Biondi
- Laura VellucciLVLaura Vellucci
Open Access
- 30 June 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (13) , 3864
Abstract
Background: Psoriatic disease, a chronic immune-mediated systemic inflammatory condition, significantly impairs patients’ quality of life. The advent of highly targeted biological therapies has transformed treatment strategies, emphasizing the importance of selecting the most effective and cost-efficient option. Secukinumab, an IL-17A inhibitor, has demonstrated efficacy and safety in treating moderate-to-severe plaque psoriasis (PsO). However, long-term real-world data on its effectiveness and persistence rate are limited. Methods: This retrospective study, conducted across eight Italian dermatology centers, aimed to evaluate the 6-year persistence rate and effectiveness of secukinumab in patients with PsO. Additionally, the study investigated the onset of psoriatic arthritis during treatment. Results: Overall, 166 adult patients were analyzed. Their median age was 53.9 years. The mean BMI was 26.5. Of the 166 patients, 64 were bio-experienced while 102 were bio-naïve. A progressive reduction in PsO severity measured by PASI scores over 6 years of treatment was revealed: the PASI score decreased from a baseline value of 18.1 (±9.1) to 0.7 (±1.6) after 6 years of follow-up. Adverse events, including mucocutaneous fungal infections and cardiovascular disturbances, were reported in 19.9% of patients. The persistence rate was 86.8% at 24 months, decreasing to 66.4% at 72 months. Psoriatic arthritis onset during treatment was observed in 15 (9.0%) of patients. Conclusions: This study highlights the sustained effectiveness and favorable safety profile of secukinumab over 6 years, providing valuable real-world evidence. Understanding the long-term persistence rate and predictors of discontinuation could help clinicians optimize treatment decisions and improve patient outcomes in PsO management. We found that the absence of scalp PsO, no involvement of the genital area and normal weight were the best factors of persistence in secukinumab treatment in the long term.Keywords
Funding Information
- Novartis (-)
This publication has 28 references indexed in Scilit:
- Treatment persistence of interleukin-17 inhibitor class drugs among patients with psoriasis in Japan: a retrospective database studyJournal of Dermatological Treatment, 2023
- P80 Real-world evidence of the effectiveness of secukinumab in patients with psoriasis with and without scalp involvement from the British Association of Dermatologists Biologics and Immunomodulators RegisterBritish Journal of Dermatology, 2023
- Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern ItalyJournal of Dermatological Treatment, 2023
- Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE StudyDermatology and Therapy, 2022
- Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort StudyAmerican Journal of Clinical Dermatology, 2022
- Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA StudyDermatology and Therapy, 2022
- In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasisExpert Opinion on Biological Therapy, 2019
- Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic ArthritisNew England Journal of Medicine, 2015
- Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2015
- Economic Burden of Psoriasis in the United StatesJAMA Dermatology, 2015